Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annpat.2011.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Goodbye, Hasta-luego, Ciao, Auf Wiedersehen, Zài jiàn, Au revoir!
Eur Ann Otorhinolaryngol Head Neck Dis
November 2024
European Annals of Otorhinolaryngology Head & Neck Diseases, Elsevier, 65, rue Camille-Desmoulins, 92130 Issy les Moulineaux, France; Service d'otorhinolaryngologie et de chirurgie Cervico-Faciale, HEGP, AP-HP, université Paris Cité, 20, rue Leblanc, 75015 Paris, France. Electronic address:
A letter to the editor: Okay, but what for?
Eur Ann Otorhinolaryngol Head Neck Dis
November 2024
European Annals of Otorhinolaryngology Head Neck Diseases, Elsevier, 65, rue Camille-Desmoulins, 92130 Issy-les-Moulineaux, France; Service d'otorhinolaryngologie et de chirurgie cervico-faciale, centre hospitalier universitaire, université Grenoble-Alpes, CS 10217, 38043 Grenoble cedex 9, France.
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
Clin Ther
August 2024
Medical Oncology Department, Program in Solid Tumours, CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, and Grupo Español de Investigación en Cancer ginecológicO (GEICO), Madrid, Spain.
Purpose: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting dose (FSD) of 300 mg once daily (QD). This analysis characterized the population pharmacokinetics (PK) of niraparib and evaluated the relationships between exposure, efficacy, and safety to support clinical use of an individualized dosing strategy, in which the starting dose of niraparib was adjusted based on patient characteristics to improve the benefit-risk profile.
View Article and Find Full Text PDFWoman is truly the future of man!
Eur Ann Otorhinolaryngol Head Neck Dis
September 2024
European Annals of Otorhinolaryngology Head & Neck Diseases, Elsevier, 165, rue Camille-Desmoulins, 92130 Issy-les-Moulineaux, France; Service d'otorhinolaryngologie et de chirurgie cervico-faciale, HEGP, AP-HP, université Paris Cité, 20, rue Leblanc, 75015 Paris, France. Electronic address:
[Not Available].
Ann Pathol
February 2024
Département de pathologie, cellulaire et tissulaire, CHU d'Angers, 4, rue Larrey, 49100 Angers, France. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!